In his EBMT 2025 presentation, Prof. Alessandro Rambaldi (University of Milan / ASST Papa Giovanni XXIII, Bergamo) offered valuable insight into one of the most pressing issues in hematologic oncology: relapse after CAR-T cell therapy in B-ALL.
While CAR-T has transformed the outlook for patients with relapsed/refractory B-ALL, Prof. Rambaldi highlighted that fewer than half of patients achieve long-term remission. This growing clinical challenge calls for a more nuanced therapeutic strategy.
He emphasized that retreatment strategies should be tailored to the immunophenotypic profile of relapse. Options include anti-CD19 or CD22 antibodies, newer academic CAR-Ts, and menin inhibitors for cases involving KMT2A rearrangements. For patients achieving remission, allogeneic HCT remains a critical curative path.
Thank you, Prof. Rambaldi, for shedding light on the evolving therapeutic landscape and future directions for managing post-CAR-T relapse in B-ALL.
For more insights, visit: https://lnkd.in/eHjN-Vcb
